Our Programs
MD2 Biosciences is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics in oncology, and pulmonary fibrosis. We are pursuing product candidates with a solid scientific rationale to address a high unmet need in oncology and pulmonary fibrosis and an opportunity to develop best-in-class or first-in-class programs.
01
Colorectal Cancer
Approximately 90% of sporadic CRCs contain mutations in components of the Wnt/β-catenin signaling pathway. These mutations are found in the earliest neoplasms, suggesting that this pathway is a critical gatekeeper to prevent colorectal carcinogenesis.
02
Gastrointestinal Stromal Tumors
The wnt/β-catenin signaling pathway is essential in the malignant transformation of GIST and thus overexpressed in GIST.
03
Brain Cancer
β-catenin is known to induce transcriptional expression of PD-L1 to promote glioma immune invasion.
04
Pulmonary Fibrosis
Aberrant activation of Wnt/β-catenin signaling occurs in all fibrotic lung diseases and could be a potential target for novel treatment approaches.
